<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401139</url>
  </required_header>
  <id_info>
    <org_study_id>HREC 15009</org_study_id>
    <nct_id>NCT02401139</nct_id>
  </id_info>
  <brief_title>Ketamine Trial for the Treatment of Depression</brief_title>
  <official_title>Ketamine Therapy Among Patients With Treatment-resistant Depression: a Randomised, Double-blind, Placebo-controlled Trial: Pilot Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of New South Wales</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Randomized Controlled Trial, investigating the safety and efficacy of
      administration of ketamine as a potential treatment for depression.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale for Depression (MADRS)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Unipolar Depression</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Individuals will be eligible for enrolment on the basis of:

          -  major depressive disorder for at least three months duration

          -  an inadequate response to at least 2 adequate antidepressants

          -  MADRS â‰¥ 20

        Patients will be excluded on the basis of:

          -  History of psychosis

          -  History of bipolar disorder

          -  Any unstable medical or neurologic condition

          -  Any Axis I disorder other than MDD judged to be primary presenting problem

          -  Planned major changes to psychotropic medication

          -  Significant risk of suicide

          -  Planned or probable use of ECT

          -  Age under 16 years, or 16-17 years without parental consent

          -  Substance abuse or dependence in previous 6 months

          -  Any history of abuse of ketamine or phencyclidine

          -  Contraindication to the use of ketamine

          -  Planned use of ketamine

          -  Women of childbearing potential not taking reliable contraception

          -  Likely non-compliance with trial treatment

          -  Other condition judged by the treating clinician as likely to impact on the ability of
             the participant to complete the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colleen K Loo, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New South Wales</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veronica Galvez Ortiz, MBBS, MD</last_name>
    <phone>+61-2-93823720</phone>
    <email>v.galvezortiz@unsw.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angelo Alonzo, PhD</last_name>
    <phone>+61-2-93822987</phone>
    <email>a.alonzo@unsw.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brain &amp; Mind Research Institute (BMRI), University of Sydney</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nick Glozier</last_name>
      <phone>(02) 9351 0536</phone>
      <email>nick.glozier@sydney.edu.au</email>
    </contact>
    <investigator>
      <last_name>Nick Glozier, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Black Dog Institute, University of New South Wales</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Galvez</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of New South Wales</investigator_affiliation>
    <investigator_full_name>Colleen Loo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

